Chymase participates in chronic dermatitis by inducing eosinophil infiltration.
An epicutaneous application of 2,4-dinitrofluorobenzene (DNFB) to a mouse ear caused a transient skin swelling, and the repetition of the challenge enlarged the contact dermatitis. The repeated challenge with DNFB also induced eosinophil infiltration on the application site. Administration of a chymase inhibitor significantly inhibited the ear swelling as well as eosinophil accumulation. An intradermal injection of human chymase to the mouse ear also elicited transient skin swelling and eosinophil infiltration, both of which were augmented in proportion to the number of injections. Human serum albumin and heat-inactivated chymase failed to induce such skin reactions, suggesting the participation of proteolytic activity of the enzyme. In addition, chymase stimulated eosinophil migration in vitro in a concentration-dependent manner. Taken together, these observations suggest that mast cell chymase may contribute to development of the DNFB-induced dermatitis, probably by promoting eosinophil infiltration. It is therefore possible that chymase plays a role in pathogenesis of chronic dermatitis such as atopic dermatitis.
Tomimori
Yoshiaki
Y
Suntory Biomedical Research Limited, Wakayamadai, Shimamoto-cho, Mishima-gun, Osaka, Japan.
Muto
Tsuyoshi
T
Fukami
Harukazu
H
Saito
Kayo
K
Horikawa
Chika
C
Tsuruoka
Nobuo
N
Saito
Masayuki
M
Sugiura
Namino
N
Yamashiro
Kyoko
K
Sumida
Motoo
M
Kakutani
Saki
S
Fukuda
Yoshiaki
Y
D000287:Administration, Topical; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity; D000818:Animals; D053818:Chymases; D003877:Dermatitis, Contact / Q000188:drug therapy / Q000201:enzymology* / Q000276:immunology; D004139:Dinitrofluorobenzene / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004431:Ear, External / Q000187:drug effects / Q000473:pathology; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004802:Eosinophilia / Q000188:drug therapy / Q000201:enzymology* / Q000276:immunology; D004804:Eosinophils / Q000201:enzymology* / Q000276:immunology / Q000473:pathology; D006968:Hypersensitivity, Delayed; D007271:Injections, Intradermal; D008213:Lymphocyte Activation; D051379:Mice; D008809:Mice, Inbred C3H; D011239:Prednisolone / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012697:Serine Endopeptidases / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology
D000485:Allergens; D004791:Enzyme Inhibitors; D011480:Protease Inhibitors; D011239:Prednisolone; D004139:Dinitrofluorobenzene; D012697:Serine Endopeptidases; D053818:Chymases